Wednesday, 01 Apr 2020

Biologic/Novel Rx

Date Typesort ascending Title Save
20 Mar 2016 Social Tofacitinib meets primary endpoints in ulcerative colitis trials, achieving 16-18% remission rates https://t.co/mkWZTfz213
21 Nov 2019 Social FINCH3: FILGOTINIB studied in this cohort naive to MTX; interesting that safety data looks good! Maybe too early to tell. Abst# 927 https://t.co/AonswiGYG3 https://t.co/q3OU582WbT
15 Jun 2018 Social RT @CreakyJoints: US physicians are more prone to continue biologics through pregnancy. Per a research poster presented at #EULAR2018 https…
28 Aug 2015 Social FDA issues guidance document- Nonproprietary Naming of Biological Products (includes biosimilars) http://t.co/lsLmHbQS0t
06 May 2016 Social A FREE Patient Guide to Biologic Use - available now at the RheumNow Website. 13 pages jammed with Patient Education https://t.co/f4BJvLu84N
29 Nov 2016 Social Good, basic overview of Biosimilars. https://t.co/N0hE8xL8Ga
05 Nov 2017 Social RT @HealioRheum: Maternal #biologic use did not increase risk for opportunistic infections in #newborns https://t.co/1Iaj1awDK0 #ACR17 http…
08 Oct 2018 Social "Therapeutic Update: Biosimilars in Rheumatology" video series features nine experts talking about biosimilars, sponsored by Sandoz, Inc. Visit RheumNow to watch: https://t.co/1vmnEJqOSi #biosimilars https://t.co/WM1EINjFGy
17 Jan 2020 Social Analysis of worldwide data on Abatacept shows that compared with other bDMARDs, ABA was not associated with an increased overall cancer risk [ROR 0.98 (95% CI 0.91, 1.05)], but may be increased for risk of melanoma [1.58 (95% CI 1.17, 2.08)] https://t.co/3EI52M5kIR
13 Feb 2020 Social RT @Janetbirdope: Adalimumab seeems better than infliximab Behcet’s uveitis. Alvin Wells #RWCS2020 @RheumNow https://t.co/dYrKyNjASB
14 Apr 2017 Social Are there issues with BIOSIMILAR Safety, Switching or Cost? Patient survey: please vote 5 quick questions here https://t.co/ZvCVlif6Ij
27 Aug 2019 Social Olumiant (baricitinib) meets its primary endpoint in a phase 3 trial in moderate to severe atopic dermatitis (AD). The BREEZE-AD7 study is one of 5 phase 3 studies in the BREEZE-AD programme. https://t.co/FOO2bIzeVA
23 Mar 2020 Social Considerations on how to do biologic infusions in Rheum patients - "Infusions in the time of corona" by Dr. Eric Ruderman.
23 Nov 2015 Social The new Etanercept biosimilar (SB4) in the EU is named Benepali, EMA recommended for RA, PsA, SpA & plaque psoriasis https://t.co/6tbvbO7cHY
22 Jul 2016 Social In Tofacitinib RCTs 1821 child-bearing age F exposed; 47 pregnant (33 monoRx). 1 Pulm valve stenosis, 7 Spont Abs. https://t.co/O2GT1BKiMT
02 Aug 2017 Social FDA Arthritis Advisory Panel votes against (12-2) approval of Sirukumab (IL6 inhib) for use in RA. FDA decision pending.
05 May 2017 Social Japan Study shows 8mg IV Actemra can be escalated to q3 wks IV or reduced to q5 wks IV according to q4wk response https://t.co/rLn6aJowry
12 Nov 2019 Social RT @philipcrobinson: Yes, you read that right US$5,000,000,000 increase in biological DMARD spending #ACR19 @RheumNow Abs 2731 https://t.co…
03 May 2018 Social Sandoz biosimilar version of rituximab set back by a complete response letter from the FDA delaying development of their RTX biosimilar; same recent fate as Celltrions RTX biosimilar. https://t.co/EkikDMU1u8
08 Jun 2015 Social 967 pts Orencia RA registry (ORA) shows SIE rate 4.1/100PY. Predictive factors: age & # prior SIE or recurrent infx http://t.co/wrucZOW9HC